Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down - Time to Sell?

Key Points

• Hikma Pharmaceuticals shares experienced a significant **gap down**, opening at $23.52 after closing at $24.50, with the last trade recorded at $23.25.
• BNP Paribas initiated coverage with an **"outperform" rating**, contributing to the overall average rating of **"Buy"** for the stock.
• The company's current financial ratios include a **quick ratio of 0.72** and a **debt-to-equity ratio of 0.33**, indicating relatively stable liquidity and leverage positions.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $24.50, but opened at $23.52. Hikma Pharmaceuticals shares last traded at $23.25, with a volume of 640 shares changing hands.

Analyst Ratings Changes

Separately, BNP Paribas initiated coverage on shares of Hikma Pharmaceuticals in a research note on Tuesday, May 13th. They issued an "outperform" rating on the stock. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy".

Hikma Pharmaceuticals Stock Performance

The stock's fifty day moving average price is $26.09 and its 200-day moving average price is $26.65. The company has a quick ratio of 0.72, a current ratio of 1.24 and a debt-to-equity ratio of 0.33.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.